Acadia to Present Phase 2 Remlifanserin Data in Alzheimer's Psychosis at CTAD 2026

By Public Technologies
  • Acadia Pharmaceuticals will present Phase 2 remlifanserin findings in Alzheimer's disease psychosis at CTAD in Boston, November 16-19, 2026.
  • The ongoing RADIANT trial's efficacy and safety findings are scheduled for an oral presentation November 17 at 9:35 a.m. ET.
  • A separate poster will examine biomarker heterogeneity in clinically diagnosed Alzheimer's disease psychosis patients negative for amyloid proteinopathy and p-Tau217.
  • The poster presentation is scheduled for November 18, from 7:15 a.m. to 5:30 p.m. ET.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. ACADIA Pharmaceuticals Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 202611091605BIZWIRE_USPR_____20261109_BW488285) on November 09, 2026, and is solely responsible for the information contained therein.

Capital Com is an execution-only service provider. The present material must be regarded as marketing communication and should not be interpreted as investment research or investment advice. Any opinion that may be provided on this page does not constitute a recommendation by Capital Com or its agents. We do not make any representations or warranty on the accuracy or completeness of the information that is provided on this page. If you rely on the information on this page, then you do so entirely at your own risk